Great Summary, one thing's for sure IXR are moving at a great...

First 69 Last

Share
Profile

Follow
roblun

5,673 Posts.

2229

24/04/24

19:17

Post #: 73504423
Share

Originally posted by jake0002: ↑

Goodaye there Docmin,
If we want to highlight issues surrounding constant CR's, just look at 88E !

With IXR, there are a number of issues, most of which have already been raised here.

1. the very large level of discount to SP.
2. the price of 1.3c.
3. the fact that it was a Placement in which the Chairman participated.
4. the fact it was a Placement, which deliberately excluded other shareholders. Noting Boards are supposed to treat all shareholders equally.
5. the clear view that the allocation of Options are clearly too cheap. ie not on commercial terms in my personal opinion. Are the terms of this CR intended to curry favour with certain clients, for later CRs?
6. On what basis did the Board agree to selectively place shares to our Chairman? They need to explain just how and why that occurred - because they need to keep s/h on-side for the vote.
7. what information did ALL the participants in the Placement receive in order for them to subscribe in Placement. No one will persuade me that a director is not privy to info that the rest of the market does not have. Witness to comments re Offtakes etc etc.

We all know that one needs 5% of capital to do a 249D. I suspect that no one here has access to that many shares.

In any event, I would not support removal of our Board - WHY?, because many reasons. The issue that they have ignored retail shareholders in this CR is fair comment --- but IMHO, the fact remains that they are getting IXR moving at a rapid pace.

Bottom line here is if they get the SP up because they get Makuutu firing, and Ionic Tech firing, we ALL win.

If we all are angry about the selective CR (as I am) then we ALL have a chance to vote against the various resolutions when the EGM is held in June.

If the resolutions fail, then the Board will get the message, and the Chair will not get his shares.

We need to keep an eagle eye on the wording of those resolutions.

Remember, these people would not be committing their cold hard cash if the company and its business prospects were poor !!!

Expand

Great Summary, one thing's for sure IXR are moving at a great pace with Belfast and Makuutu, two demonstration Plants up and running producing REO + MREC 24/7 (with two Feasability Studies) products being produced and tested by OEM's and potential Partners which is a very big plus in this situation, must be very close to signing some sort of deal. Like Ive mentioned before we need a very impressive rock solid Announcement very soon to have some sort of confidence going forward.

IXR Price at posting: 1.5¢ Sentiment: Buy Disclosure: Held
14 Upvote

1 Great analysis

Reply

Top Stories

PNN

Power boosts Brazilian portfolio with Tântalo acquisition

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BPH

BPH Energy’s David Breeze addresses PEP 11 setback in company update

MXR

Maximus sniffs 3.21 g/t gold at Hilditch ahead of resource update

LDX

Lumos sees respiratory test FebriDx reach wide US audience with MediGroup contract

There are more pages in this discussion • 43 more messages in this thread...

First 69 Last

Add IXR (ASX) to my watchlist

(20min delay)
Last 0.8¢		Change -0.001(6.25%)		Mkt cap ! $36.52M

Open	High	Low	Value	Volume
0.8¢	0.8¢	0.8¢	$8.278K	1.037M

Buyers (Bids)

No.	Vol.	Price($)
46	18458647	0.7¢

Sellers (Offers)

Price($)	Vol.	No.
0.8¢	1357066	6

View Market Depth

No.	Vol.	Price($)
45	17858647	0.007
24	16230116	0.006
50	16343233	0.005
18	11481265	0.004
9	12582332	0.003

Price($)	Vol.	No.
0.008	1307066	5
0.009	8807064	15
0.010	7415175	13
0.011	3683883	6
0.012	2449999	4

Last trade - 15.15pm 25/09/2024 (20 minute delay)

IXR (ASX) Chart

Great Summary, one thing's for sure IXR are moving at a great...

Power boosts Brazilian portfolio with Tântalo acquisition

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BPH Energy’s David Breeze addresses PEP 11 setback in company update

Maximus sniffs 3.21 g/t gold at Hilditch ahead of resource update

Lumos sees respiratory test FebriDx reach wide US audience with MediGroup contract

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Great Summary, one thing's for sure IXR are moving at a great...

Top Stories

Power boosts Brazilian portfolio with Tântalo acquisition

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BPH Energy’s David Breeze addresses PEP 11 setback in company update

Maximus sniffs 3.21 g/t gold at Hilditch ahead of resource update

Lumos sees respiratory test FebriDx reach wide US audience with MediGroup contract

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News